A Multicenter Clinical Evaluation of Safety and Efficacy of Lumason as a Contrast Agent in Pediatric Echocardiography
Phase: PHASE3
Conditions: Heart Disease
Sponsor: Bracco Diagnostics, Inc

 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 1 
 
 
LumasonTM 
Protocol GM&RA 
 
 
 
CONFIDENTIAL 
A Multicenter Clinical Evaluation of Safety and Efficacy of LumasonTM/ 
as a Contrast Agent in Pediatric Echocardiography 
 
LUMASONTM  
 
Protocol No.: 
IND No. 
 
 
BR1-140  
46,958 
 
Final Version 
20th October 2014 
SPONSOR MEDICAL EXPERT:  
Melda S. Dolan, MD, FECC, FESE 
 
 
 
 
 
 
 
 
 
                                                          
 
 
 
 
 
Bracco Diagnostics Inc  
 
 
 
 
The information contained in this document is the property of Bracco Group.  It contains strictly confidential information and no part of this document 
will be published or disclosed without Bracco Group prior written permission except that this document may be disclosed to appropriate Institutional 
Review Board/Ethics Committee/Regulatory Authorities/Competent Authorities as long as they are required to keep it confidential. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 2 
 
Table of Contents 
List of Tables .................................................................................................................................. 5 
List of Figures ................................................................................................................................. 6 
List of Appendices .......................................................................................................................... 7 
Abbreviations and Definition of Terms .......................................................................................... 8 
1 
Title of Study ....................................................................................................................... 10 
2 
Protocol Number ................................................................................................................. 10 
3 
Introduction ......................................................................................................................... 10 
4 
Study Objectives .................................................................................................................. 12 
5 
Investigational Plan ............................................................................................................. 13 
5.1 
Overall Study Design Description ................................................................................ 13 
5.2 
Discussion of Study Design ......................................................................................... 13 
5.2.1 
Risk-Benefit Considerations ................................................................................. 14 
5.3 
Study Duration ............................................................................................................. 15 
5.4 
Study Population .......................................................................................................... 15 
5.4.1 
Inclusion Criteria ................................................................................................... 15 
5.4.2 
Exclusion Criteria .................................................................................................. 15 
5.4.3 
Discontinuation Criteria ........................................................................................ 16 
6 
Investigational Product ........................................................................................................ 16 
6.1 
Description and Labeling ............................................................................................. 16 
6.2 
Storage .......................................................................................................................... 17 
6.3 
Blinding and Randomization ........................................................................................ 17 
6.4 
Handling and Preparation ............................................................................................. 17 
6.5 
Administration .............................................................................................................. 18 
6.6 
Accountability .............................................................................................................. 18 
7 
Methodology ........................................................................................................................ 19 
7.1 
Study Schedule ............................................................................................................. 19 
7.2 
Written Informed Consent ............................................................................................ 19 
7.3 
Subject Numbering ....................................................................................................... 20 
7.4 
Subject Evaluations ...................................................................................................... 20 
7.4.1 
Medical History ..................................................................................................... 20 
7.4.2 
Pregnancy Test ...................................................................................................... 20 
7.4.3 
Concomitant Medications ..................................................................................... 20 
7.4.4 
Safety Assessments ............................................................................................... 21 
7.4.4.1 
Adverse Events ............................................................................................... 21 
7.4.4.2 
Physical Examination ..................................................................................... 21 
7.4.4.3 
Vital Signs ...................................................................................................... 21 
7.4.4.4 
Laboratory Evaluations .................................................................................. 21 
7.4.4.5 
Electrocardiograms ........................................................................................ 22 
7.4.4.6 
Pulse Oximetry and ECG Monitoring ............................................................ 22 
7.4.4.7 
Sedation .......................................................................................................... 22 
7.5 
Imaging Procedures ...................................................................................................... 23 
7.6 
Pharmacokinetic Evaluation ......................................................................................... 23 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 3 
 
7.7 
Efficacy Evaluations..................................................................................................... 24 
8 
Reporting Safety Information .............................................................................................. 26 
8.1 
Adverse Events ............................................................................................................. 26 
8.1.1 
Definitions ............................................................................................................. 26 
8.1.2 
Expedited Reporting a Serious Adverse Event to Sponsor ................................... 28 
8.1.3 
Breaking the study blind ....................................................................................... 29 
8.1.4 
Data Collection ...................................................................................................... 29 
8.1.5 
Subject Follow-up ................................................................................................. 31 
8.2 
Special Situations ......................................................................................................... 31 
8.3 
Laboratory Evaluations ................................................................................................ 32 
8.3.1 
Reporting and Evaluation of Central Laboratory Test Results ............................. 32 
8.3.2 
Repeat Testing ....................................................................................................... 32 
8.3.3 
Emergency Laboratory Analysis ........................................................................... 33 
8.4 
Electrocardiograms ....................................................................................................... 33 
8.5 
Physical Examinations ................................................................................................. 33 
8.6 
Vital Signs .................................................................................................................... 33 
9 
Statistical Methods .............................................................................................................. 33 
9.1 
Subject Disposition and Demographic and Baseline Characteristics ........................... 34 
9.2 
Analysis Population ...................................................................................................... 34 
9.3 
Concomitant Medications............................................................................................. 34 
9.4 
Extent of Exposure ....................................................................................................... 34 
9.5 
Safety Analysis ............................................................................................................. 34 
9.6 
Pharmacokinetics Analysis........................................................................................... 35 
9.7 
Efficacy Analysis ......................................................................................................... 35 
9.7.1 
Primary Efficacy Endpoints - Anatomical Characteristics ................................... 35 
9.7.2 
Analysis Methods .................................................................................................. 35 
9.7.2.1 
Analysis of LV EBD Score ............................................................................ 35 
9.7.2.2 
Analysis of LV Opacification ........................................................................ 36 
9.8 
Sample Size .................................................................................................................. 36 
9.9 
Data Handling............................................................................................................... 37 
9.10 
Interim Analyses........................................................................................................... 37 
10 
Ethics and Good Clinical Practice ....................................................................................... 37 
10.1 
Ethical and Regulatory Compliance ............................................................................. 37 
10.2 
Informed Consent and Subject Information ................................................................. 37 
10.3 
Institutional Review Board/Ethics Committee Approval ............................................. 38 
10.4 
Financial Disclosure ..................................................................................................... 38 
11 
Administrative Considerations ............................................................................................ 38 
11.1 
Regulatory Requirements–Sponsor/Investigator Obligations ...................................... 38 
11.2 
Sponsor Regulatory Obligations for SUSARs Reporting ............................................ 38 
11.3 
Protocol Amendment .................................................................................................... 39 
11.4 
Curriculum Vitae .......................................................................................................... 39 
11.5 
Administrative Structure .............................................................................................. 39 
11.6 
Protocol Deviations, Violations and Exceptions .......................................................... 39 
11.7 
Monitoring Procedures ................................................................................................. 39 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 4 
 
11.7.1 
Study Monitoring .................................................................................................. 39 
11.7.2 
Case Report Form .................................................................................................. 40 
11.7.3 
Inspection and Auditing ........................................................................................ 40 
11.8 
Archiving of Records ................................................................................................... 40 
11.9 
Study Results ................................................................................................................ 41 
11.10 Use and Publication of Study Results .......................................................................... 41 
11.11 Financing ...................................................................................................................... 41 
11.12 Change in Investigator.................................................................................................. 41 
11.13 Definition of the End of the Study ............................................................................... 41 
11.14 Premature Termination of the Study ............................................................................ 42 
11.15 Information Material .................................................................................................... 42 
11.16 Insurance ...................................................................................................................... 42 
12 
Confidentiality ..................................................................................................................... 42 
13 
Protocol Acceptance ............................................................................................................ 43 
14 
References ........................................................................................................................... 44 
 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 5 
 
List of Tables 
 
Table A: 
Description of Investigational Product ...................................................................... 17 
Table B: 
Study Schedule ........................................................................................................... 19 
Table C: 
Laboratory Analytes ................................................................................................... 22 
Table D: 
Adverse Events Reporting – Sponsor Contact Personnel .......................................... 28 
 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 6 
 
List of Figures 
 
Figure 1  
Three echocardiographic apical views used in the study ........................................... 25 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 7 
 
List of Appendices 
Appendix A: Investigational Product Labeling 
Appendix B: Investigational Product Preparation 
Appendix C: Serious Adverse Event Report 
Appendix D: Investigator Statement 
Appendix E: Administrative Structure 
 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 8 
 
Abbreviations and Definition of Terms 
AE 
Adverse Event 
ALT 
Alanine aminotransferase 
AHA 
American Heart Association 
APTT 
Activated Partial Prothrombin Time 
ASE 
American Society of Echocardiography 
ASD 
Atrial Septal Defect 
AST 
Aspartate aminotransferase 
BMI 
Body Mass Index 
Co 
Centigrade 
CEUS 
Contrast Enhanced Ultrasound 
CFR 
Code of Federal Regulation 
CI 
Confidence Interval 
CMR 
Cardiac Magnetic Resonance 
CRF 
Case Report Form 
CRM 
Clinical Research Manager 
CRO 
Contract Research Organization 
CTR 
Clinical Trial Report 
DICOM 
Digital Imaging and Communications in Medicine  
DPPG.Na 
Dipalmitoyl phosphatidylglycerol sodium  
DSPC 
Distearoylphosphatidylcholine  
EBD 
Endocardial Border Delineation 
ECG 
Electrocardiogram 
Fo 
Farenheit 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GC-MS 
Gas Chromatography-Mass Spectrophotometry 
GGT 
Gamma-Glutamyl Transpeptidase 
h 
Hour 
HLHS 
Hypoplastic Left Heart Syndrome 
IB 
Investigator’s Brochure 
ICH 
International Conference on Harmonization 
IND 
Investigational New Drug 
IP 
Investigational Product 
IRB 
Institutional Review Board 
ITD 
Intention  to Diagnose 
Kg 
Kilogram 
LDH 
Lactic Acid Dehydrogenase 
LV 
Left Ventricle / Left Ventricular 
LV EBD 
Left Ventricular  Endocardial Border Delineation 
LVEF 
Left Ventricular Ejection Fraction 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 9 
 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
Milligram 
MI 
Mechanical Index  
min 
Minute 
mL 
Milliliter 
ng 
Nanogram 
PEG 
Polyethylene Glycol 
PT 
Prothrombin Time 
QRS 
Q−wave — depolarization of the ventricular septum  
R−wave — activation of most of the ventricle  
S−wave — last stage of ventricular depolarization  
QT 
measure of the time between the start of the Q wave and the end of the T wave in the 
heart's electrical cycle 
QTc 
QT corrected for heart rate 
RBC 
Red Blood cell Count (total erythrocyte count) 
ROW 
Rest of the World 
RR 
Time between beats used to calculate heart rate 
SAER 
Serious Adverse Event Report 
SAP 
Statistical Analysis Plan 
SAS 
Statistical Analysis Software 
SF6 
Sulfur hexafluoride 
SGOT 
Serum Glutamic Oxaloacetic Transaminase 
SGPT 
Serum Glutamic Pyruvic Transaminase 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TOF 
Tetralogy of Fallot 
2D 
Two dimensional 
WBC 
White Blood Cell Count (total leukocyte count) 
WHO 
World Health Organization 
UEUS 
Unenhanced Ultrasound 
ul 
Microliter 
USA 
United States of America 
VSD 
Ventricular Septal Defect 
w/v 
Weight/ Volume 
w/w 
Weight/ Weight 
βHCG 
Beta Human Chorionic Gonadotropin 
 
   

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 10 
 
1 
Title of Study 
A MULTICENTER CLINICAL EVALUATION OF SAFETY AND EFFICACY OF 
LUMASONTM  AS A CONTRAST AGENT IN PEDIATRIC ECHOCARDIOGRAPHY 
2 
Protocol Number 
This study is being conducted under protocol number: BR1-140. 
IND number: 46,958. 
3 
Introduction 
 
Echocardiography has become the primary imaging tool in the diagnosis and assessment of 
congenital and acquired heart disease in children and adolescents.1 Even though technically 
challenging echocardiographic windows are a more common challenge in adults, there is also a 
similar subset of children who do have limited, technically suboptimal echocardiographic 
windows secondary to obesity, congenital heart disease, chest wall abnormalities or prior 
surgical interventions resulting in suboptimal echocardiograms.2 
Clinical trials have shown that suboptimal echocardiograms defined as non-visualization of at 
least 2 or more contiguous segments in the standard echocardiographic views 3 can be converted 
to a diagnostic study with the use of contrast in 75% to 90% of patients with fundamental and 
harmonic imaging modalities used.4-8 For more than a decade, intravenous contrast 
echocardiography has been demonstrated to be a very useful tool in optimizing endocardial 
border delineation (EBD) in the adult population.9-16  Ultrasound contrast is not approved by the 
Food and Drug Administration (FDA) for use during pediatric echocardiography because the 
safety and efficacy of contrast agents have not been established definitively in children.17 
Although the reported clinical use of transpulmonary contrast agents in the pediatric population 
is limited, the utility of these agents in pediatric population can be quite valuable.18,19 Contrary to 
general belief, children do not always have diagnostic echocardiographic studies. Furthermore, 
dealing with children, especially sick children, presents a unique challenge. Children are 
frequently frightened and need coaxing and distractions to cooperate with the study. In addition, 
pediatric cardiologists have less training in regional wall-motion interpretation during stress 
echocardiography than their counterparts in adult cardiology.17  These factors make contrast 
agents valuable in evaluating pediatric patients, particularly those who routinely undergo serial 
echocardiographic studies including stress echocardiograms (such as patients with Kawasaki 
disease,20 those who have undergone the arterial switch operation, other coronary reimplantation 
surgery or cardiac transplantation), because contrast agents facilitate EBD.17, 18, 19, 21  
Congenital heart defects are serious and common conditions that have significant impact on 
morbidity, mortality, and healthcare costs in children. The most commonly reported incidence of 
congenital heart disease is between 4 and 10 per 1000, averaging 8 per 1000 live births.  An 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 11 
 
estimated minimum of 32,000 infants are expected to be affected each year in the United States 
of America (USA).  Of those, an approximate 25%, or 2.4 per 1000 live births require invasive 
treatment in the first year of life. Furthermore, congenital cardiovascular defects are the most 
common cause of infant death resulting from birth defects; >24% of infants who die of a birth 
defect have a heart defect.  The 2008 death rate attributable to congenital cardiovascular defects 
was 1.1. Infant mortality rates under one year of age were ranging from 34.9 to 46.5.22 
Congenital heart defects range in severity from small holes between chambers that may resolve 
spontaneously to major malformations that can require multiple surgical procedures before 
school age and may result in death in infancy or in childhood. The most common complex 
defects include Tetralogy of Fallot (TOF), Transposition of the great arteries (TGA), atrial and 
ventricular septal defects (ASD/VSD), Coarctation of the aorta, Hypoplastic left heart syndrome 
(HLHS). 22 In children born with complex congenital heart disease, functional evaluation of the 
ventricle is often necessary and becomes challenging.17 Poor acoustic windows in pediatric 
population often limit transthoracic images particularly for those have undergone surgical repair.  
Ultrasound contrast agents can be helpful in EBD of these geometrically unusual chambers, 
thereby aiding in functional assessment. These pediatric population groups include patients after 
procedures to repair TOF and after the Senning and Mustard procedures.17, 18, 19, 21 The growing 
population of patients with congenital heart disease has led to a markedly increased use of non-
invasive cardiac imaging in their care.23 These patients often have residual structural and 
hemodynamic abnormalities, which necessitate serial comprehensive assessment, but 
transthoracic echocardiography is often challenging due to acoustic window limitations 
secondary to previous cardiac operations, implanted pacemaker leads, and alterations in the 
geometry due to shunts and baffles. Furthermore, these patients undergo cardiac magnetic 
resonance (CMR) imaging due to limitation of echo without contrast enhancement, if they do not 
have pacemaker, but the artifacts produced by implanted metal prevent assessment of imaging of 
cardiac structures within several centimeters of the stainless coils which are often used to 
occlude undesirable collateral vessels.24 
In a recently published study,21 efficacy of ultrasound contrast both at rest and stress has been 
prospectively studied in 51 patients with congenital heart disease some of which were children. 
Results of this particular study indicated that ultrasound contrast at rest and stress echo enabled 
safe and comprehensive assessment of anatomy and biventricular function by improving EBD in 
all patients with an increased number of wall segments visualized.21 
Similarly, McMahon et al 19 demonstrated the safety of using contrast echocardiography in 20 
children ranging in age from 9 to 18 for the evaluation of congenital heart disease, or cardiac 
function in children with arrhythmia or undergoing chemotherapy. Significant improvement in 
border delineation in all myocardial segments with the concomitant use of contrast and harmonic 
imaging has been reported. More importantly, significant reduction in interobserver variability of 
ejection fraction using harmonic imaging and contrast echocardiography versus fundamental or 
harmonic imaging alone without contrast was shown.19 McMahon et al provided further evidence 
that the use of contrast agents is safe, improves accuracy of evaluation of cardiac function, and 
helps to better delineate the endocardial border of specific segments in children.19 Given the ever 
increasing demand for acquisition of high quality echocardiographic data in children with cardiac 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 12 
 
problems, contrast echocardiography plays an important role as a useful non-invasive diagnostic 
tool in obtaining accurate evaluation of anatomic and functional assessment.19 
McMahon et al studied series of 70 children with a median age of 10.3 with suboptimal 
echocardiographic windows. The use of harmonic imaging and fundamental imaging without 
contrast usage has been compared. Scores for harmonic imaging were significantly higher for all 
views in comparison to fundamental imaging in children.2 The improvement of the image quality 
obtained with harmonic imaging in children 2 is similar to the results of studies in adults.13, 25-28 
Recent studies indicate that contrast enhanced two dimensional (2D) echocardiography with 
harmonic imaging had excellent correlation with radionuclide, magnetic resonance and 
computed tomographic measurements of Left ventricular (LV) volumes and left ventricle 
ejection fraction (LVEF) with improved interobserver agreement and physician interpretation 
confidence compared to unenhanced harmonic imaging in adult population.29, 30 Furthermore, 
increasing accuracy of LVEF measurements have been associated with contrast-enhanced 
harmonic imaging over unenhanced harmonic imaging and fundamental imaging, 
respectively.31,32  
Due to the increased use of transthoracic echocardiography as a non-invasive cardiac imaging 
tool in children and an increasing number of suboptimal, non-diagnostic quality studies mostly 
due to previous cardiac operations and alterations to cardiac anatomy especially in congenital 
heart disease patients, we aim to study the safety and efficacy of Lumason™  (sulfur 
hexafluoride lipid-type A microspheres) for injectable suspension in children 9-17 years with 
suboptimal images undergoing resting transthoracic echocardiogram with harmonic imaging 
modality. LumasonTM (under the trade name SonoVue®) is approved for use in echocardiography 
both at rest and stress in the European Union (EU) for use in the adult population. No Ultrasound 
Contrast Agent is currently approved in the pediatric population for use in rest echocardiography 
to improve LV EBD in patients with suboptimal unenhanced imaging. 
4 
Study Objectives 
Primary Objective: 
• To assess the efficacy of LUMASON enhanced transthoracic echocardiography [CEUS]  
in pediatric subjects with suboptimal Left Ventricular Endocardial Border Delineation 
(LV EBD) at unenhanced transthoracic echocardiography [UEUS] in terms of: 
o Change from baseline [UEUS] versus [CEUS] in total LV EBD score. 
o Proportion of subjects with adequate LV opacification 
Secondary Objective: 
• To obtain safety data in pediatric subjects administered LUMASON for LV EBD 
improvement during echocardiography. 
• To obtain pharmacokinetic data in a subset of pediatric subjects undergoing analysis of 
SF6 concentration in blood. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 13 
 
5 
Investigational Plan 
5.1 
Overall Study Design Description 
This is a Phase III multicenter, open-label study that will be conducted at approximately 7-12 
sites in the United States in pediatric subjects with suboptimal LV EBD on non-contrast 2D 
transthoracic echocardiography with harmonic imaging within 30 days of the LUMASON 
administration. It is estimated that 92 subjects will be enrolled to provide 73 evaluable subjects. 
Three cardiologists unaffiliated with enrolling centers (blinded readers), blinded to the subject’s 
identity and clinical profile will independently evaluate the echocardiograms. The efficacy 
analysis will be primarily based on the blinded reader evaluations. 
Imaging conditions will be representative of those used in routine clinical practice and will 
include LV EBD with harmonic imaging modality. 
One or two of the sites participating in this study will also be requested to consent a subset of 
subjects for additional blood sampling for analysis of SF6 concentration (Pharmacokinetic sub-
set) in blood from a total of 6 subjects (3 males and 3 females) in the age group 9 up to 12 years 
of age and 6 subjects (3 males and 3 females) in the age of >12 up to and including 17 years. 
5.2 
Discussion of Study Design 
The current study is designed to assess the efficacy of LUMASON enhanced echocardiography 
vs. unenhanced echocardiographic imaging in pediatric population (age 9 to 17 years) with 
suboptimal images and assess the proportion of subjects with “adequate” LV opacification. The 
subjects to be enrolled in the current study are representatives of those who could benefit most 
from contrast-enhanced echocardiography. 
Echocardiography has become the primary and ideal tool for cardiac assessment and serial 
follow up of ventricular size and function as it is non-invasive, portable and efficacious in 
providing detailed anatomic, hemodynamic and physiologic information about the pediatric 
heart.2 There has been an increasing number of sub-optimal, non-diagnostic quality studies 
mostly due to previous cardiac operations and alterations to cardiac anatomy due to shunts and 
baffles especially in congenital heart disease patients, which necessitate serial comprehensive 
assessment of their residual structural and hemodynamic abnormalities.1, 3, 17, 21, 23 
The current guidelines of American Heart Association (AHA) 3 and American Society of 
Echocardiography (ASE) 17 suggest application for ultrasound contrast use in difficult to image 
patients with suboptimal image quality at their presenting rest echocardiography exams. Both 
guidelines define suboptimal studies when two contiguous segments are not visualized in any 
three of the apical views. The same criteria will be applied in children and representative of those 
used in routine clinical practice and will include assessment of LV EBD using harmonic imaging 
modality. Commercially available echocardiographic equipment and transducers will be used for 
all patients. Patients must have undergone a previous transthoracic echocardiogram with 
harmonic imaging modality within the one month period prior to enrollment resulting in 
suboptimal LV EBD in order to be included in the study. Subjects who are enrolled in the study 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 14 
 
will then undergo a pre-injection (baseline) echocardiogram with the standard apical 4-, 2-, and 
3-chamber views obtained with harmonic imaging. A recording of 2D transthoracic harmonic 
echocardiography images will be performed from 30 seconds prior to injection of LUMASON  
and then continue until all contrast enhanced images are acquired.  
The first primary efficacy endpoint of LUMASON studies (change from baseline in total of LV 
EBD score) is the one prospectively defined and agreed upon with the FDA for the adult studies. 
A LV 17-segment model will be utilized as recommended by ASE guidelines.17, 3 The standard 
views of a 2D echocardiogram as defined by the ASE are all used as part of pediatric 
echocardiogram.1, 17  The clinical utility of improvement in LV EBD resulting from opacification 
of LV as an aid in determination of more clinically relevant parameters is recognized by the 2008 
ASE consensus statement as leading to improvement in feasibility, accuracy, and reproducibility 
of echocardiography for the qualitative and quantitative assessment of LV structure and 
function.17 
The co-primary efficacy endpoint (adequacy of LV opacification following injection) will be 
graded according to the 4-point rating scale (see section 7.7). Useful appearance of contrast 
within the LV including ventricular opacification rating of +2 (non-homogeneous) or +3 
(complete and homogeneous) will be considered as adequate LV opacification. 
A subset of 12 subjects is considered to be sufficient for the estimation of the pharmacokinetic 
parameters, based on the findings of a prior study in healthy adult subjects.33 
In adults, the dose for LV opacification is a fixed dose of 2 mL. Assuming a notional adult body 
weight of 70 kg, this represents a dose of 0.03 mL/kg body weight. This dose will be used for the 
study in pediatric population. 
Most or all of contrast agent dose rapidly dissolves in the blood and subsequently eliminates by 
the lungs.  The cumulative recovery of SF6 in expired air averaged 86% to 94% of the 
administered dose in healthy subjects.33 The results of this study published by Morel et al 36 had 
shown that LUMASON rapidly removed from the blood by the pulmonary route with 40% to 
50% of the injected dose eliminated within the first minute after administration and 80% to 90% 
eliminated by 11 minutes after administration. Furthermore, the recovery of SF6 in expired air in 
subjects with impaired lungs averaged 102%.34 This finding indicates that the patients eliminate 
all of the SF6 from LUMASON via their lungs rather than an alternate elimination route, despite 
the impairment of lung function. Most alveolar maturation occurs in the first 2 years of life, so 
that no differences in the elimination of the gas between adults and pediatric patients 9-17 years-
old should be expected.35 No studies ever reported the use of ultrasound contrast agents during 
rest echocardiography in patients below 9 years of age. 
5.2.1 
Risk-Benefit Considerations 
A benefit from contrast-enhanced LV EBD resulting in improved 36 diagnostic quality of 
echocardiographic examinations should be expected. Given the fact that the subjects to be 
enrolled in the present clinical trial will be already scheduled for echocardiographic examination 
but with suboptimal images and have no evidence of intracardiac shunts, inclusion in the study is 
not likely to add any risk for the subjects, since no particular safety concerns can be expected 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 15 
 
when administering LUMASON to children with respect to the safety profile of LUMASON. 
Furthermore, contrast enhanced transthoracic echocardiogram supposed to prevent the risk of 
those subjects being exposed to radiation through other imaging modalities in the down 
streaming of appropriate assessment of cardiac structures. 
5.3 
Study Duration 
The procedure associated with the investigational echo exam prior to and after the administration 
of the investigational product will be completed within approximately 15-30 minutes. 
Safety monitoring will begin at the time of signing Informed Consent (and subject’s “assent,” 
according to requirements by local regulations), and will continue for 72 hours post dose. 
5.4 
Study Population 
The study will be conducted in subjects who have sub-optimal images from transthoracic 
harmonic echocardiography. It is expected that approximately 7-12 study centers in the United 
States will participate in the study. Each site may enroll approximately 20 subjects in this trial. 
Approximately 92 subjects will be enrolled in order to obtain 73 evaluable subjects. 
5.4.1 
Inclusion Criteria 
Enroll a subject in the study if they meet the following inclusion criteria: 
• Is male or female, 9 to 17 years of age; 
• Written informed consent is obtained from the subject’s parent(s) or legal acceptable 
representative(s) (according to local regulations); 
• Assent from the subject is obtained when applicable, that is, when it is required according 
to local regulations (IRB requirements) (see section 10.2); 
• Is suspected of having cardiac disease or undergoing evaluation of cardiac anatomy for 
congenital heart disease;  
• Has undergone a previous transthoracic echocardiogram within a one month period prior to 
enrollment in this study resulting in suboptimal LV EBD defined as >2 contiguous 
segments in any given view that cannot be visualized. 
5.4.2 Exclusion Criteria 
Exclude a subject from this study if the subject does not fulfill the inclusion criteria, or if any of 
the following conditions are observed: 
• Children < 9 years of age; 
• Has previously been enrolled in this study;  
• Has been administered any other contrast agent either intravascularly or orally within 48 
hours of the first LUMASON administration; 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 16 
 
• Has known right-to-left, bidirectional or transient cardiac shunt, (ruled out with agitated 
saline study performed before administration of LUMASON) ; 
• Has any known hypersensitivity to one or more of the ingredients of the investigational 
product (sulfur hexafluoride or to any components of LUMASON); 
• Has received an investigational compound within 30 days before enrolling into this study; 
• Is a pregnant or lactating female. Exclude the possibility of pregnancy in subjects who 
have started their menses (by testing on site at the institution (urine βHCG) within 24 hours 
prior to the start of investigational product administration); 
• Is determined by the Investigator that the subject is clinically unsuitable for the study. 
5.4.3 
Discontinuation Criteria 
Clearly document the reason for the subject’s discontinuation on the Case Report Form. 
Discontinued subjects are not replaced.  Discontinue a subject from the study if the subject: 
• Withdraws consent/or assent if applicable; 
• No longer meets the Inclusion Criteria; 
• Experiences any of the Exclusion Criteria; 
• Has an adverse event that, in the opinion of the Investigator, requires the subject’s 
discontinuation.  Perform patient follow-up in accordance with Section 8.1.5. 
6 
Investigational Product  
The study investigational product (IP) is named LUMASON in the United States. The 
investigational product is supplied as a 3-part kit containing the following: 
• clear glass vial labeled as LUMASON (sulfur hexafluoride lipid-type A microspheres) 
for injectable suspension, 
• prefilled 5 mL syringe labeled as Sodium Chloride Injection, USP, 0.9% Sodium 
Chloride and its plunger rod 
• Mini-spike  
6.1 
Description and Labeling 
LUMASON is formulated as a 25 mg sterile, non-pyrogenic lyophilized powder in a septum-
sealed vial. The gas phase in the vial is SF6, an innocuous gas. The lyophilized powder is made 
of a combination of pharmaceutical grade polyethylene glycol (PEG) molecular weight 4000, 
phospholipids and palmitic acid. Phospholipids from chemical synthesis were selected for their 
higher chemical purity and lower pyrogenic potential. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 17 
 
A mixture of distearoylphosphatidylcholine (DSPC) and dipalmitoyl phosphatidylglycerol 
sodium (DPPG.Na) is used in the IP. 
Following reconstitution, the injectable suspension contains 1.5 to 5.6 x 108 microspheres/mL. 
 Table A: Description of Investigational Product 
Ingredient 
Concentration / Amount per Unit 
Polyethylene glycol (PEG) 4000 
4.91 mg/mL 
Phospholipids (DSPC/DPPG 1:1 w/w) 
0.075 mg/mL 
Palmitic Acid 
0.008 mg/mL 
Sulfur Hexafluoride (SF6) 
8 µL/mL 
 
Investigational product will be supplied by Bracco. Labeling will be done according to the 
National Legal requirements of each country where the study may be conducted. Each vial will 
bear a two-part label, the second part of which once used will then need to be affixed to the 
appropriate page of the Case Report Form (Appendix A). 
6.2 
Storage 
Store unused LUMASON vials in a secure area with limited access at controlled room 
temperature at 25°C (77°F), excursions are permitted to 15-30 °C (59-86°F) 
6.3 
Blinding and Randomization 
This is an open-label, non-randomized study. 
6.4 
Handling and Preparation 
Prior to administration, the lyophilized powder should be reconstituted with 5 mL of sterile 0.9% 
w/v sodium chloride solution to give a final concentration of 8µL of SF6 lipid microspheres per 
mL. After adding the sodium chloride solution, the vial should be shaken vigorously for 20 
seconds, after which a homogeneous white milky liquid is obtained. A detailed instruction for the 
reconstitution of LUMASON is presented in (Appendix B). 
Once reconstituted, LUMASON can be left at room temperature. The suspension is usable for up 
to 3 hours, upon standing for more than 15 minutes, buoyancy causes some of the larger 
microspheres to rise to the surface. Therefore, gently agitate the reconstituted LUMASON vial in 
a top-to-bottom manner to resuspend the sulfur hexafluoride lipid microspheres before 
administration. The desired volume of the product is then withdrawn into a syringe for 
administration to the subject. 
In the case of incomplete use of vial contents, the product cannot be reused. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 18 
 
6.5 
Administration 
Once reconstituted, LUMASON will be administered intravenously as a single 0.03 mL/kg bolus 
injection during echocardiography. The LUMASON injection will be followed immediately with 
5 mL of saline to flush the intravenous line of any remaining contrast agent. 
6.6 
Accountability 
In accordance with International Conference of Harmonization (ICH) and United States FDA 
requirements, the Investigator and/or Drug Dispenser must at all times be able to account for all 
IP furnished to the institution.  The appropriate site personnel must sign, date and immediately 
forward to the Sponsor the IP receipt form included with each shipment. 
No IP is to be used outside of this study.  Record the use of the IP on the appropriate Drug 
Accountability Record. All containers of IP must be accounted for, whether used or unused, 
during the course of and at the conclusion of the study.  At the conclusion of the study, all 
shipments of unused IP to the Investigator must be returned to the Sponsor accompanied by a 
completed, signed copy of the appropriate IP inventory reconciliation form. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 19 
 
7 
Methodology 
7.1 
Study Schedule 
 
Table B: Study Schedule 
 
Pre dose 
Post dose 
Within 
-24 h 
Within 
-30 min 
e 
Prior to IP 
administration 
0 min 
5 min 
30 
min  
24 h 
72 h 
Written Informed Consent a 
 
 
 
 
 
 
 
 
Adverse Events Monitoring b 
 
 
 
 
 
 
 
 
Concomitant Medications c 
 
 
 
 
 
 
 
 f  
Medical History 
 
 
 
 
 
 
 
 
Physical Examination 
 
 
 
 
 
 
 
 
Vital Signs  
 
 
 
 
 
  
 
 
Pregnancy Test (if necessary) 
 
 
 
 
 
 
 
 
Pulse Oximetry/ ECG 
monitoring d 
 
 
 
 
 
 
 
 
 
Laboratory Evaluations  
 
 
 
 
 
 
 
 
12-Lead Electrocardiogram   
 
 
 
 
 
 
 
 
IP Administration 
 
 
 
 
 
 
 
 
Unenhanced Echo 
 
 
x 
 
 
 
 
 
Contrast Enhanced Echo 
 
 
 
 
 
 
 
 
a Obtain prior to implementation of any study procedure. 
b Start monitoring from the time Informed Consent is given up to 24 h post dose and continue monitoring up to 72 hrs post dose 
through a telephone call placed at Day 3. Only post dose events will be tabulated as adverse events. 
c For any subject where sedation is administered, record the sedation medication on the concomitant page of the CRF and 
indicate for sedation. 
d Continuous pulse oximetry and ECG monitoring will be performed 30 min prior through 30 minutes following IP 
administration for all subjects suffering from pulmonary hypertension or unstable cardiopulmonary conditions.  
e For any subject where sedation is administered, obtain a second vital sign series and ECG immediately before the 
echocardiography exam and after the sedation drugs have been administered. 
f  Record any new medication taken for treatment of an adverse event that occurred after the signed informed consent was 
obtained through 72 hours following IP administration. 
 
Note: A subset of 12 subjects will undergo additional blood draws for analysis of SF6 concentrations, (see Section 7.6). 
 
7.2 
Written Informed Consent 
Obtain written Informed Consent from the subject’s parent(s) or legal acceptable 
representative(s) (according to local regulations) prior to the implementation of study procedures 
required by the protocol. Obtain written Assent from the subject, when it is required by local 
IRB. Give to the subject’s parent (s) or legal acceptable representative(s) a copy of the signed 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 20 
 
and dated written informed consent form including any other written information regarding the 
study. Document Informed Consent process (Assent when applicable) in detail, in the source 
record at the site. 
Separate written Informed Consent (Assent when applicable) is needed for those subjects who 
participate in the Pharmacokinetic subset. 
7.3 
Subject Numbering 
Assign a 4-digit subject number for each subject who qualifies for the study and signs the written 
Informed Consent.  The first two digits of the subject number will be the investigational site 
number assigned by Sponsor.  For site numbers less than ten use a leading zero. The third and 
fourth digits will be a number starting with 01 for the first subject enrolled and incrementing by 
“1” for each sequential subject. 
For example, at site 01, the investigative site will assign the first subject 0101; the second subject 
0102, etc. 
Never reassign subject numbers.  In the event that a subject withdraws from the study, the 
number assigned to that subject is retired and the next subject receives the next sequential 
number. 
7.4 
Subject Evaluations 
7.4.1 
Medical History 
Obtain a complete medical history after the subject has signed the Informed Consent and within 
24 hours prior to IP administration.  Record the subject’s medical history on the Medical History 
section of the Case Report Form. 
7.4.2 
Pregnancy Test  
If the subject is female, and of child bearing potential, exclude the possibility of pregnancy by 
testing (urine βHCG) within 24 hours prior to the start of IP administration. 
7.4.3 
Concomitant Medications 
Record all medications (prescription and over-the-counter) taken within 24 hours prior to IP 
administration in the Concomitant Medication section of the Case Report Form. Record newly 
prescribed pharmacological treatments in this section from within 30 minutes prior to IP 
administration up through 24 hours post investigational product administration. Additionally, any 
new medication taken for treatment of an adverse event that occurred after the subject signed 
informed consent through 72 hours following IP administration should be recorded. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 21 
 
7.4.4 
Safety Assessments 
7.4.4.1 
Adverse Events 
Monitor subjects for any untoward medical events from the time of signed Informed Consent 
through 72 hours after investigational product administration. 
Subjects will be evaluated at up to 72 hours post dose either by telephone call made by a 
healthcare professional, or by a scheduled, follow up visit.  
Record all untoward medical events in the Adverse Event section of the Case Report Form as 
specified in Section 8. Only post dose untoward medical occurrences will be tabulated as adverse 
events. 
7.4.4.2 
Physical Examination 
Perform a physical examination within 24 hours prior to IP and at 24 hours after IP 
administration. 
7.4.4.3 
Vital Signs 
Collect the following vital signs within 30 minutes pre dose and at 5 minutes, 30 minutes and 24 
hours post dose.  Obtain the following vital signs in a position that is consistent for all time 
points for each subject: 
• Systolic blood pressure (mmHg)  
• Diastolic blood pressure (mmHg) 
• Heart rate (beats/minute) 
• Respiratory rate (breaths/min) 
7.4.4.4 
Laboratory Evaluations 
Collect blood samples within 24 hours prior to the investigational product administration and 24 
hours after the IP administration. A central laboratory will perform evaluations for the analytes 
listed in Table C.  

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 22 
 
Table C: Laboratory Analytes 
Hematology 
Clinical Chemistry 
Hematocrit 
Sodium 
AST/SGOT 
Hemoglobin 
Potassium 
ALT/SGPT 
RBC count 
Chloride 
Alkaline Phosphatase 
WBC count 
Glucose 
GGT 
differential WBC count 
Urea Nitrogen 
Uric Acid 
Platelets 
Creatinine 
Total Protein 
PT 
Total Bilirubin 
Albumin 
APTT 
LDH 
Calcium 
 
Prepare blood and ship via overnight courier per the Instruction Manual provided by the central 
laboratory. 
7.4.4.5 
Electrocardiograms 
A 12-Lead Electrocardiogram (ECG) will be performed in all subjects within 30 minutes prior to 
IP administration, and at 30 minutes and 24 hours after IP administration and a copy of the ECG 
report will be affixed to the CRF. 
The ECG examinations will be evaluated by a central ECG laboratory that will provide the ECG 
equipment to the site and will employ a cardiologist to perform the centralized ECG evaluation 
containing the following information: 
• RR interval 
• PR interval 
• QRS interval 
• QT and QTc interval (Bazett’s and Fridericia’s) 
• Overall diagnostic assessment 
• Comparison to Baseline 
7.4.4.6 
Pulse Oximetry and ECG Monitoring 
Continuous pulse oximetry and ECG monitoring will be performed starting 30 min prior and 
continuing through 30 minutes following IP administration for all subjects suffering from 
pulmonary hypertension or unstable cardiopulmonary conditions. 
7.4.4.7 
Sedation 
When children are unable to cooperate, sedation may become necessary to ensure that images of 
diagnostic quality are obtained. Whether or not sedation is necessary depends on several 
variables, including age and maturity of the subject, prior sedation history, duration of the 
procedure, and any associated discomfort. Subjects will be sedated or anesthetized only for 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 23 
 
procedural purposes and then according to standard hospital routines by qualified individuals 
(e.g., nurses, physicians, or physician assistants) who are experienced in the management of 
sedated children and have the knowledge to perform careful subject screening so as not to put 
any subject at unacceptable risk of serious complications. 
All drugs administered for sedation will be recorded on the Case Report Form on the 
Concomitant Medications page. Monitoring of the subject will start with documentation of pre-
sedation vital signs, and ECG recordings on the Case Report Form. Continuous subject 
monitoring should be conducted according to routine clinical practice. When sedation is 
required, additional vital signs and ECG data will be performed after sedation and before the 
echocardiography examination and recorded on the CRF. 
Whenever adverse events are recorded, the Investigators will be asked to prospectively report in 
the CRF their causality assessment including an evaluation of whether the event may be related 
to the sedation drug(s) or the IP. 
7.5 
Imaging Procedures 
At each site, the same commercially available echocardiographic equipment and transducers will 
be used for all subjects. Subjects will be examined in either the supine or lateral decubitus 
position. The transmit power (≤ 0.8 MI) and the gain setting will be adjusted at the beginning of 
each procedure to obtain optimal endocardial visualization. Both settings must be kept constant 
throughout each subject’s evaluation. Every effort must be made to keep the optimal transducer 
position for standard views. At each site, image acquisitions can be performed by the same 
sonographer throughout the study. 
Prior to administration of IP, further evaluation for intracardiac shunt will be demonstrated with 
agitated saline study to assess the interatrial septum. If no evidence of intracardiac shunt is 
confirmed by the pediatric cardiologist, the subject will further undergo CEUS. 
A pre-injection (baseline) UEUS with the standard apical 4, 2, and 3 views with harmonic 
imaging will be performed. Contrast-enhanced echocardiography will be performed with 
administration of the IP. A recording of 2D transthoracic harmonic echocardiography images 
will be performed from 30 seconds prior to injection of the IP and continued until all images are 
acquired. For CEUS images, the apical 4-chamber view will be acquired first followed by the 
apical 2- and 3-chamber views.  
Both the UEUS and CEUS examinations must be identified by subject number and stored as 
DICOM clips for transfer to the central imaging lab according to the instructions provided in the 
Imaging Manual. The investigational sites are also required to maintain a copy of the subject’s 
examination as a record of the study. 
7.6 
Pharmacokinetic Evaluation 
A subset of subjects at one or two sites will undergo additional blood sampling for the 
determination of SF6 concentration in blood. A total of 6 subjects (3 males and 3 females) age 9 
and up to 12 years of age, and 6 subjects (3 males and 3 females) in the age >12 and up to and 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 24 
 
including 17 years will have additional blood draws of 1 mL each immediately pre-dose, and at 
1, 2, 3, 5, 10 and 15 minutes post-dose for the purposes of analyzing SF6 concentration in blood. 
Blood samples will be taken from the arm contralateral to that used for the injection of 
LUMASON and analyzed by gas chromatography-mass spectrometry (GC-MS) or other 
acceptable method to obtain SF6 concentration in blood.  A designated laboratory will perform 
evaluations of SF6. 
7.7 
Efficacy Evaluations  
For all subjects, UEUS and CEUS images will be randomized and independently evaluated off-
site by 3 blinded readers unaffiliated with the enrollment centers. No on-site evaluation of 
efficacy will be performed for this study.  
From the apical 4-chamber, apical 2-chamber and apical long (3-chamber) views, the heart will 
be divided into 17 segments according to the guidelines of the American Society of 
Echocardiography17 as seen in Figure 1. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 25 
 
Figure 1  Three echocardiographic apical views used in the study 
 
EBD for each segment will be graded by each off-site reader as: 
 
0 = Inadequate (endocardial border not visible) 
 
+1 = Sufficient (endocardial border barely visible) 
 
+2 = Good (endocardial border clearly visible). 
A separate off-site methodology document will be prepared and will contain the details regarding 
how the images will be anonymized, randomized and presented to the readers. No clinical 
information will be provided to the readers. 
Both the UEUS and CEUS examinations must be identified by subject study identification 
number and stored as DICOM clips for transfer to the central imaging lab according to the 
instructions provided. Under Good Clinical Practices guidelines, the investigational sites are also 
required to maintain the subject’s examination as a record of the study. 
The timing of LV EBD assessment should start when LUMASON reaches from the apex to the 
mitral valve plane level. 
The degree of LV opacification following injection will be graded according to the following 4-
point rating scale: 
 
  0 = none, i.e., no visible contrast within the left ventricular cavity 
 
+1 = faint, i.e., weak or trace effect of contrast within the left ventricle 
 
+2 = non-homogeneous, i.e., some areas of the left ventricle fully opacified but without a 
time when the whole cavity is filled with contrast to the same high intensity 
 
+3 = complete, homogeneous and high intensity effect. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 26 
 
Useful appearance of contrast within the left ventricle including ventricular opacification rating 
of +2 (non-homogeneous) or +3 (complete and homogeneous) will be considered as adequate LV 
opacification. 
8 
Reporting Safety Information 
The Investigator is responsible for the detection, documentation and reporting of adverse events. 
Adverse event (AE) collection begins when a subject signs the Informed Consent and continues 
through the follow-up period defined in the Section 7.4.4.1 “Adverse Events” of the protocol. In 
addition, an investigator should report any serious AEs that occur after this time period that 
he/she believes may be related to the IP. 
Any untoward medical occurrence that occurs from the time of signed Informed Consent to the 
time immediately prior to investigational product administration will be tabulated in the Clinical 
Trial Report as a “pre dose event.”   
8.1 
Adverse Events 
8.1.1 
Definitions 
An AE is any untoward medical occurrence in a subject or a clinical trial subject administered a 
medicinal product and which does not necessarily have to have a causal relationship with the use 
of the product.  
Any AE that occurs after the follow-up period defined in the protocol is not required to be 
collected in the AE section of the CRF.  
An existing condition, which is detected by the diagnostic procedure conducted to test the 
efficacy of an investigational contrast agent, is not considered an AE. 
Symptoms or medically significant laboratory or instrumental (e.g., electrocardiographic) 
abnormalities of a pre-existing condition, such as cancer or other disease, should not be 
considered an AE. However, new symptoms and laboratory or instrumental abnormalities, as 
well as worsening of pre-existing ones are considered AEs. 
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:  
• results in death,  
• is life-threatening (i.e. the subject was at risk of death at the time of the event/reaction; it 
does not refer to an event/reaction which hypothetically might have caused death if it were 
more severe), 
• requires inpatient hospitalization or prolongation of existing hospitalization,  
• results in persistent or significant disability/incapacity (where disability is defined as a 
permanent or substantial disruption of ability to carry out normal life functions, either 
reported or defined as per clinical judgment), 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 27 
 
• is a congenital anomaly/birth defect,  
• is an important medical event that may not result in death, be life-threatening, or require 
hospitalization but may be considered serious when, based upon appropriate medical 
judgment, it may jeopardize the subject and may require medical or surgical intervention to 
prevent any of the outcomes listed in the definition above.  Examples of such events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, and blood dyscrasias or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse.  
Any suspected transmission via a medicinal product of an infectious agent is also considered an 
SAE. 
A non-serious AE is any AE that does not meet the criteria listed above for a SAE. 
The reference safety document will be the same for the whole clinical trial. 
An unexpected AE is one where the nature, severity, specificity or outcome is not consistent with 
the applicable product reference document. 
In particular, the Sponsor will determine the expectedness of the AEs reported during this 
clinical trial according to the following reference document(s): 
LUMASON: latest version of the Investigator’s Brochure (IB).This will be provided as a 
separate document. 
If an updated version of the reference safety document becomes available during the conduction 
of the study and before the last subject out, the Sponsor will provide the new version to all 
investigators. The new version will become the reference safety document for assessing the 
expectedness of AEs’. 
An AE with fatal outcome should be considered unexpected unless the reference safety 
document specifically states that the event might be associated with a fatal outcome.  
When it is uncertain whether an AE is expected, the AE should be treated as unexpected. 
Upon notification of a serious AE, the Sponsor reviews all of the information provided by the 
Investigator and will urgently seek additional information when needed.  The Sponsor will 
determine expectedness of the serious AE according to the latest version of the IB. 
Reporting of serious AEs to the FDA will be done by the Sponsor according to the applicable 
and current Code of Federal Regulations (CFR). Additionally, any unexpected related serious 
adverse events will be reported to the investigators and Institutional Review Boards (IRBs) 
participating in the study as required by the applicable FDA CFR. 
Whenever a serious AE is reported which is considered to be related to IP and unexpected based 
on the current IB, in addition to reporting to FDA, IRBs/Ethics Committees and Investigators as 
stated above, the Sponsor will review all available safety data to determine whether or not the 
study should be placed on hold and/or additional urgent safety measures added to the protocol. 
Any action taken in response to a safety concern will be communicated to FDA. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 28 
 
8.1.2 
Expedited Reporting a Serious Adverse Event to Sponsor 
The Investigator must report all serious adverse events within 24 hours, by telephone or by fax, 
to both the Drug Safety group and the Clinical Manager of the Sponsor as listed in Table D.  
A Serious Adverse Event Report (SAER), see (Appendix C) must be completed by the 
Investigator and faxed to the Sponsor (both the Drug Safety group and the Clinical Manager) 
within 3 calendar days after the Investigator first became aware of the serious event.  The top 
two copies of the completed SAER should also be sent to the Sponsor by traceable mail.  The 
bottom copy remains on-site with the CRF.  
In case of death, a comprehensive narrative report of the case should be prepared by the 
Investigator and sent to both the Drug Safety group and the Clinical Manager of the Sponsor by 
traceable mail together with the SAER, with a copy retained on-site with the CRF.  If an autopsy 
is performed, a copy of the autopsy report should be actively sought by the Investigator and sent 
to the Sponsor as soon as available with a copy retained on-site with the CRF. 
A follow-up SAER should be filled in by the Investigator if important follow-up information 
(e.g., diagnosis, outcome, causality assessment, results of specific investigations) becomes 
available after submission of the initial SAER.  The follow-up SAER should be sent to the 
Sponsor in the same manner and following the same timeline as described for the initial.  
If the Investigator becomes aware of any serious adverse events within the follow-up window 
established in the protocol following investigational product administration, they will be reported 
to both the Drug Safety group and the Clinical Manager of the Sponsor as described above. 
If outside the follow-up window established in the protocol, any serious adverse events are 
reported to the Investigator, which he/she believes are related to the administration of the IP it is 
the Investigator’s responsibility to report this serious adverse event to both the Drug Safety 
group and the Clinical Manager of the Sponsor. Such serious adverse events will be reported 
using a SAER or any other way chosen by the Investigator. Do not use the CRF. 
The names, telephone, fax numbers, and email address of the contact persons are given below in 
Table D: 
Table D: Adverse Events Reporting – Sponsor Contact Personnel 
Name/Title 
Office Telephone 
Number 
Alternate Telephone 
Number 
Fax Number / E-mail 
North America 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
* To be used outside the normal business hours. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 29 
 
 
For additional SAE questions call the Medical Expert whose contact details are on the cover 
page of the protocol. 
8.1.3 
Breaking the study blind 
This is an open-label, non-randomized study 
8.1.4 
Data Collection 
The Investigator will collect adverse events through non-leading questions and examination of 
the subjects. 
For each event, record the following information in the Adverse Event section of the Case Report 
Form: 
• Classification of the Event: Classify the event as either serious or non-serious (see 
definitions in Section 8.1.1). 
• Description of Signs or Symptoms: Whenever possible, record a specific diagnosis for 
the event.  If a diagnosis cannot be made, then record each sign or symptom separately. If 
multiple episodes of an event occur, separated by an appropriate time interval to justify 
considering the subsequent episodes as a repeat occurrence, record each episode separately 
on the Case Report Form.  Indicate if the event is local (i.e., occurring at the site of 
administration). For serious AEs only: provide a detailed chronological description of the 
clinical course of the event(s) and of all relevant signs and symptoms. 
• Onset Date and Time: Record the date and time the event started.  If a change from pre 
dose in a laboratory test is reported as an adverse event, record the start date as the date of 
collection of the first lab sample that shows the change. 
• Stop Date and Time: Record the date and time the event resolved.  If a change from pre 
dose in a laboratory test is reported as an adverse event, record the stop date as the date of 
collection of the first post dose sample that shows a return to the pre dose level. 
• Intensity:  
1. Mild: Event not resulting in disability/incapacity, which resolves without treatment. 
2. Moderate: Event not resulting in disability/incapacity, which requires treatment. 
3. Severe: Event resulting in temporary and/or mild disability/incapacity, which 
requires treatment. 
• Relationship to the IP:  Make every effort to determine the cause of each adverse event.  
Classify the correlation between the IP and the adverse event as follows: 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 30 
 
1. Reasonable 
Possibility 
The event falls into one of the two following categories: 
 
1)  a) The event follows a reasonable temporal sequence 
from administration of the IP;  
 
 
 
 
 
AND 
    b) The event follows a known response pattern to the IP 
but could have been produced by any of the following 
features:  
• the subject’s clinical state, or 
• other therapy administered, or 
• the diagnostic/interventional procedure; 
  
 
 
OR 
    c) The event cannot be reasonably explained by any of the 
following features: 
• the subject’s clinical state, or 
• other therapy administered, or 
• the diagnostic/interventional procedure; 
  
 
 
OR 
       d) There is evidence of partial or complete disappearance    
of the event after withdrawal of the product (positive 
dechallenge). 
 
2)    The report of the event contains: 
       a) conflicting data  
AND/OR 
       b) dubious or insufficient/poor evidence 
2. No reasonable 
Possibility 
The event is either a pre dose event or is definitely due to 
causes separate from the administration of the IP, i.e., 
• documented pre-existing condition 
• technical and manual procedural problems 
• concomitant medication 
• the subject’s clinical state 
• the event is judged as not related and does not fall 
under either of the categories for “reasonable 
possibility” 
• erroneous administration of treatment 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 31 
 
• Action Taken:  
0. None 
1. Change in the investigational product administration (including brief interruption of 
administration of total dose and early termination of administration, i.e., dose 
reduction) 
2. Drug treatment required (a medication was prescribed or changed; record in the 
Concomitant Medication section of the Case Report Form) 
3. Non-drug treatment required (a non-drug treatment was prescribed or changed, record 
under “Comments” in the Adverse Event section of the Case Report Form) 
4. Hospitalization or prolonged hospitalization 
5. Diagnostic or clinical test(s) conducted (attach a copy of the results to the Case 
Report Form)  
6. Subject discontinued from the study 
• Subject Outcome:   
1. Recovered without sequelae 
2. Recovered with sequelae (describe the sequelae under “Comments” in the Adverse 
Event section of the Case Report Form) 
3. Not Recovered, event on-going (follow the subject until a definite outcome can be 
determined.  When follow-up data are collected, report follow-up information under 
“Comments” in the Adverse Event section of the Case Report Form; if the event is 
serious, fill in a follow-up Serious Adverse Event Report) 
4. Died (list primary cause of death under “Event Description” in the Adverse Event 
section of the Case Report Form; if available, attach a copy of the autopsy report to 
the Case Report Form and send a copy to Sponsor) 
• Comments: 
Provide other pertinent clinical information and observations, and the rationale for the 
provided causality under “Comments” in the Adverse Event section of the Case Report 
Form.  For example, record predisposing or contributing conditions, such as previous 
history, concomitant diseases or medications, and/or procedural risks and explain the 
reasoning for attributing the event(s) to the cause chosen.  
If the investigator states that there is no reasonable possibility that the event is related, 
he/she should provide details of an alternative explanation for the event.  
8.1.5 
Subject Follow-up 
Make every attempt to follow the subject until the adverse event is resolved, stabilized, returned 
to baseline or deemed irreversible. 
8.2 
Special Situations 
The Investigator must report all special situations within 24 hours by telephone or by fax using 
the form supplied by the Sponsor, to both the Drug Safety group and the Clinical Manager of the 
Sponsor as listed in Table D. 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 32 
 
Special situations include but are not limited to the following: accidental overdose of IP, 
medication error with IP (such as administration of the wrong drug or wrong dose, wrong 
administration rate or wrong technique in drug usage process, administration via the wrong 
route, radiation under-dose, labeled drug-drug or drug-disease or drug-food interaction). In 
addition, any pregnancy of a subject or partner must be reported by the Investigator to the 
Sponsor within 24 hours using the Pregnancy Report form; any associated SAEs must be 
reported concurrently using the SAER.   
In case urgent safety measures are taken during the conduct of the study these will be timely 
communicated by the Sponsor to the applicable regulatory authorities and also to concerned 
investigators and subjects. 
8.3 
Laboratory Evaluations 
8.3.1 
Reporting and Evaluation of Central Laboratory Test Results 
The central laboratory will send a report of the laboratory results to the Investigator within 48 
hours after the sample is picked up from the investigational site.  Attach a copy of the laboratory 
report to the Case Report Form.  
The Investigator or sub-investigator must review laboratory values within 24 hours of receipt of 
the laboratory report. After the review is completed, the Investigator must sign and date each 
laboratory report. 
The central laboratory will provide normal reference ranges for the laboratory tests on the 
laboratory results report.  A value is normal when it falls on or within the upper and lower limits 
of the reference range.  A value is abnormal when it falls outside the upper or lower limit of the 
reference range.  The central laboratory will flag all abnormal values on the laboratory report and 
will verify that the result is not due to pre-analytical problems (e.g., sample taken improperly, 
sample stored incorrectly, sample labeled incorrectly) or to analytical problems (e.g., machine 
not accurately calibrated, technical problems with equipment or reagents, deterioration of 
analyte).   
The central laboratory has established ‘alert criteria’ for some laboratory tests and will make an 
immediate telephone call to the Investigator in the event that a laboratory result meets these 
criteria. 
The Investigator must evaluate any change from pre dose to post dose in a laboratory test which 
represents a worsening of the subject’s clinical state as to whether it meets the definition of an 
adverse event.  Record all changes determined to meet the definition of an adverse event in 
the Adverse Event section of the Case Report Form.   
8.3.2 
Repeat Testing 
Collect additional samples to repeat the lab test that represents a worsening of the subject’s 
clinical state and meets the definition of an adverse event, until the value returns to the pre dose 
level or clinically stabilizes, or until the Investigator or physician of record determines that 
further follow-up is unnecessary. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 33 
 
8.3.3 
Emergency Laboratory Analysis 
If a laboratory result needs to be obtained immediately, split the sample and send one-half to the 
local laboratory for immediate analysis and the other half to the central laboratory.  Attach 
results from both laboratories to the Case Report Form. 
8.4 
Electrocardiograms 
If a worsening from pre dose to post dose is observed on an ECG, repeat the ECG at the 
discretion of the Investigator, in addition to obtaining an ECG at the 30 min and 24 hours post 
dose time points required by the protocol.  The Investigator will assess any worsening from pre 
dose to post dose in the ECG for clinical relevance (whether it meets the definition of an adverse 
event).  Record all changes determined to meet the definition of an adverse event in the Adverse 
Event section of the Case Report Form. 
8.5 
Physical Examinations 
If a worsening from pre dose to post dose is observed, repeat the physical examination at the 
discretion of the Investigator, in addition to obtaining a physical examination at the 24 hour post 
dose time point required by the protocol. The Investigator will evaluate any worsening at the post 
dose physical examination for their clinical relevance and to determine whether they meet the 
definition of an adverse event. Record all changes determined to meet the definition of an 
adverse event in the Adverse Event section of the Case Report Form. Record specific signs, 
symptoms, and/or laboratory information supporting these changes. 
8.6 
Vital Signs 
If a worsening from pre dose to post dose is observed in vital signs, repeat the vital sign 
measurement at the discretion of the Investigator, in addition to obtaining vital sign 
measurements at 5 minutes, 30 minutes and the 24 hour post dose time points as required by the 
protocol.  The Investigator will evaluate any worsening in vital signs for its clinical relevance as 
to whether it meets the definition of an adverse event.  Record all changes determined to meet 
the definition of an adverse event in the Adverse Event section of the Case Report Form. 
9 
Statistical Methods 
In general, summary statistics (mean, median, standard deviation, minimum, and maximum) will 
be provided for continuous variables, and the number and percentage of each category will be 
provided for categorical data. Any changes in the original statistical methodology will be 
documented in the statistical analysis plan (SAP).  
All statistical analyses will be performed using SAS® software. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 34 
 
9.1 
Subject Disposition and Demographic and Baseline Characteristics 
Summary tables will be provided for the number of subjects who have been enrolled, dosed and 
completed according to the protocol. The number of subjects who prematurely discontinued the 
study and the reasons for their discontinuation will be summarized.  
Summary statistics will be presented for demographic and baseline characteristics, including age, 
sex, race, height, and weight, BMI, other relevant study entry criteria. 
9.2 
Analysis Population 
Safety Analysis Population – all subjects who received IP will be included in the safety analysis 
population. 
Efficacy Analysis Population – all subjects who received IP and have data available for both 
non-contrast echo exam and contrast echo exam will be included in modified Intent-to-Diagnose 
population (ITD population).  
9.3 
Concomitant Medications 
Frequencies of concomitant medication use will be tabulated by World Health Organization 
(WHO) class, level I and level II. 
9.4 
Extent of Exposure 
Descriptive statistics will be presented to summarize the volume (mL) of IP administered. Dose 
administration for IP will be listed for each injection by subject. 
9.5 
Safety Analysis 
The safety data will be summarized for all subjects dosed. Summary tables, including change 
from UEUS to CEUS or clinically significant changes where applicable, will be presented for the 
following safety endpoints: 
• Adverse Events 
• Clinical Laboratory Evaluations 
• Electrocardiograms 
• Pulse Oximetry 
• Vital Signs 
All adverse events will be coded by MedDRA and summarized by system organ class and 
preferred term, by intensity and by causal relationship to the investigational product. 
Only those occurrences which occur from the start of IP administration through the follow-up 
period defined in the protocol will be tabulated in the Clinical Trial Report as “adverse events” 
See Section 8.1.1. 
Physical examination results, concomitant medication data will be presented in the data listings. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 35 
 
Summary statistics will be presented for volume of investigational product administered. 
9.6 
Pharmacokinetics Analysis 
Pharmacokinetic parameters will be calculated from blood data. The actual times (i.e., not the 
nominal sampling times) at which blood samples obtained will be used in all calculations. Blood 
concentrations below the limits of quantification will be replaced with zero for the calculation of 
all pharmacokinetic parameters. The blood concentration-time data will be analyzed using 
appropriate software. 
A listing of all raw blood concentration data and tables containing standard descriptive statistics 
will be reported. Profiles of blood concentrations will be represented graphically for the mean 
and individual data to show the inter-subject variability. The pharmacokinetic parameters will be 
normalized by subject body weight if applicable. Appropriate pharmacokinetic compartment/ 
non-compartment modeling will be applied based on the performance of goodness of fit criteria 
and the inter-subject variability of the subject pharmacokinetic profiles.  Pharmacokinetic 
analysis approach will be similar to the methodology utilized in the adult study 
 to be 
able to compare the results between pediatric and adult pharmacokinetic data. 
9.7 
Efficacy Analysis 
The primary analysis will be based on the off-site reader evaluations. The analysis will be 
performed and presented separately for each reader. There will be no adjustment for multiple 
readers. There will be 2 primary endpoints for the study: the change from baseline (UEUS to 
CEUS) in total LV EBD score and proportion of subjects with adequate LV opacification. As we 
have to achieve success for both endpoints there will be no multiplicity adjustment for the 
analysis and power consideration. 
9.7.1 
Primary Efficacy Endpoints - Anatomical Characteristics 
The first primary efficacy endpoint will be the change from baseline in total LV EBD scores 
(UEUS vs. CEUS). Total LV EBD score is calculated as the sum of the individual scores (0, 1, or 
2) assigned to each of the 17 segment images with a total score range 0-34.  
The co-primary endpoint will be the proportion of subjects with adequate LV opacification.  Left 
ventricular opacification will be graded as 0 to +3, 4-point rating scale. Left ventricular 
opacification rating of +2 (non-homogeneous) or +3 (complete and homogeneous) will be 
considered as adequate LV opacification. 
9.7.2 
Analysis Methods 
9.7.2.1 
Analysis of LV EBD Score 
The null hypothesis of the primary test is that there is no difference between the CEUS and 
UEUS in the mean total LV EBD score in the pediatric population. The alternative hypothesis is 
that the CEUS is superior to UEUS in term of the mean total LV EBD score in pediatric 
population.  

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 36 
 
H0:  CE -  UE = 0 
H1:   CE -  UE > 0 
where  UE represents the mean of the total LV EBD score for the UEUS; and  CE represents the 
mean of the total LV EBD score for the CEUS. 
For each blinded reader assessment, paired t-test will be used to compare total LV EBD score 
between the CEUS and UEUS. In addition, the 2-sided 95% confidence intervals (CIs) will be 
calculated for the mean total LV EBD scores for each exam as well as for the change from 
baseline (UEUS to CEUS). The distribution of the individual scores (0, 1, or 2) assigned to each 
of the 17 ventricle segments will be presented.  
The study will be considered as a success for the primary efficacy endpoint if: 2 of the 3 readers 
achieve superiority of the CEUS over the UEUS in terms of the mean total LV EBD score. The 
satisfaction of superiority is met if the alternative hypothesis is concluded, i.e., CE - UE > 0 
based on paired t-test at significance level of 0.05.  
Inter-reader agreement of the assessment for each segment among 3 off-site readers will be 
evaluated (for UEUS and CEUS separately) by kappa statistic.  
The number and percentage of subjects with reduction of inadequate LV EBD in at least one pair 
of adjacent segments (combined 4-chamber, 2-chamber, and 3-chamber view) following 
administration of IP will be summarized for each reader.  
9.7.2.2 
Analysis of LV Opacification 
The proportion and its 95% CI of subjects with adequate LV opacification scores at the CEUS 
will be estimated using binomial proportion estimate method.  Assuming expected proportion of 
subjects with adequate LV opacification scores at the CEUS is 80%.  The success criteria for the 
LV opacification score will be 2 out of 3 blinded readers reach >70% as the lower limit of 95% 
confidence limit for the proportion of subjects with adequate LV opacification score.  
Inter-reader agreement of the assessment of adequate LV opacification for each subject among 3 
off-site readers will be evaluated by kappa statistic. 
9.8 
Sample Size 
Sample size determination for this study was based on the 2-tailed paired t-test using software 
nQuery Advisor 7.0. The primary objective of this trial is to show a significant intra-subject 
change in total of LV EBD scores for each subject (Hypothesis specified above) from UEUS to 
LUMASON -enhanced echocardiography. Sample size determination for this study was based on 
the 2-tailed paired t-test. 
A peer-reviewed publication showed 37 that the percentage of endocardial border visualization at 
unenhanced harmonic images (74%) was significantly lower comparing to a contrast enhanced 
images (88%) in the suboptimal subjects non-diagnostic imaging group, which translated to the 
difference of 4 in total LV EBD scores. A previously conducted Bracco-sponsored study 
 had the same endpoint of the total LV EBD score range 0-32 assessed on harmonic 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 37 
 
images on adult subjects with known or suspected coronary artery disease. The results from the 
analysis of the suboptimal subjects in this study showed that the average difference of the total 
LV EBD score between CEUS and UEUS was 3.2; the standard deviation of the difference was 
8.3. Based on these results as the assumptions for current study and considering the probability 
of a Type I error () of 0.05 and the probability of a Type II error () of 0.10, 73 subjects will be 
needed to show a difference between CEUS and UEUS for 90% of power.  
When the sample size is 73, a 2-sided 95% CI for a single proportion using the large sample 
normal approximation will extend 9% from the observed proportion for an expected proportion 
of 80% subjects with adequate LV opacification score. This can be translated as lower limit of 
95% CI >70% for the observed proportion of subjects with adequate LV opacification score. 
Based on the above considerations, for both endpoints (Total LV EBD score and LV 
opacification score), total of 73 evaluable subjects are needed. Considering 20% of early 
dropout, 92 subjects will need to be enrolled. 
A subset of 12 subjects is considered to be sufficient for the estimation of the pharmacokinetic 
parameters, based on the findings of a prior study in healthy subjects. 
9.9 
Data Handling 
All data collected will be entered into the database and displayed in the data listings and tables. 
Detail of the data handling procedures will be specified in the SAP. Baseline values will be 
defined as the last measurement prior to administration of the IP. 
9.10 Interim Analyses 
No interim analysis is planned. 
10 Ethics and Good Clinical Practice 
10.1 Ethical and Regulatory Compliance  
The study will be conducted in accordance with the protocol, ICH, Good Clinical Practice, FDA 
regulations, ethical principles that have their origin on the Declaration of Helsinki and all 
applicable local regulations, whichever offers greatest protection for the subject. 
10.2 Informed Consent and Subject Information 
Written informed consent and permission must be obtained from the subject’s parent(s) or legal 
acceptable representative(s) prior to the implementation of study procedures required in the 
protocol. This must be done according to the guidelines provided in the Declaration of Helsinki, 
ICH E6 Guideline for Good Clinical Practice, and as applicable, the requirements of Title 21 
CFR 50.20 through 50.27 and related guidance. If the subject is capable, the subject should 
assent to having the investigational procedures, according to local regulations. This may be 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 38 
 
determined by the IRB. The board takes into account age, maturity, and psychological state. 
Assent may be site specific, as the IRB also determines how the assent is obtained. 
Give the parent(s) or the subject’s legally acceptable representative a copy of the Informed 
Consent Form and Assent if applicable. The subject’s parent(s), or legal as applicable, must be 
made aware and agree that personal information may be scrutinized during inspection or audit by 
authorities and properly authorized persons. However, personal information will be treated as 
strictly confidential and will not be publicly available. 
10.3 Institutional Review Board/Ethics Committee Approval 
The protocol, Informed Consent Form, Subject Information Sheet, if applicable, and any 
advertisement for the recruitment of subjects must be reviewed and approved by an appropriately 
constituted IRB/EC, as required in chapter 3 of the ICH E6 Guideline, and as applicable, Title 21 
CFR 56.107 through 56.115,  and related guidance. Written IRB approval must be obtained by 
Sponsor prior to shipment of investigational product or subject enrollment. 
The investigator is committed in accordance with local requirements to inform the IRB/EC of 
any emergency problem, serious adverse events, and/or protocol amendments. 
10.4 Financial Disclosure 
Financial support to Investigators/Sub-Investigators other than the cost of conducting the clinical 
study or other clinical studies will be disclosed where applicable in accordance with Title 21 
CFR 54.2 and related guidance. 
11 Administrative Considerations 
11.1 Regulatory Requirements–Sponsor/Investigator Obligations 
This study will be conducted in accordance with the Declaration of Helsinki, ICH E6 Guideline, 
and as applicable, Title 21 CFR 312.50 through 312.70 and related guidance. To ensure 
compliance the Investigator agrees, by written consent to this protocol, to fully cooperate with 
compliance checks by allowing access to all documentation by authorized individuals, and 
competent and regulatory authorities. 
11.2 Sponsor Regulatory Obligations for SUSARs Reporting 
The Sponsor shall ensure that all relevant information about suspected unexpected serious 
adverse reaction (SUSAR) which occurs during the course of the clinical trial, whether or not 
this event is fatal or life-threatening, will be reported to the applicable Regulatory Authority 
including but not limited to the FDA. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 39 
 
11.3 Protocol Amendment 
No change to the protocol may be made without the joint agreement of both the Investigator and 
Sponsor.  Any amendment to the original protocol will be signed by both parties and submitted 
to the IRB for approval or notification prior to implementation except in circumstances when it is 
necessary to implement urgent safety measures to remove an immediate hazard to the study 
subject(s). 
11.4 Curriculum Vitae 
The Investigator and any sub-investigator(s) must provide Sponsor with current copies of their 
own signed and dated curriculum vitae. 
11.5 Administrative Structure 
The administrative structure of the study (e.g., monitoring and vendor personnel, statistician, 
laboratory facilities, and clinical trial supply management) is presented in (Appendix E). A 
complete and controlled list of the Investigators, study sites, and IRB’s involved in this study can 
be found in the Trial Master File maintained by the Sponsor. 
11.6 Protocol Deviations, Violations and Exceptions  
As a matter of policy, Bracco will not grant exceptions to protocol-specific entry criteria to allow 
subjects to enter a study.  If investigative center personnel learn that a subject who did not meet 
protocol eligibility criteria was entered in a study they must immediately inform Bracco. 
If a violation is serious, the CRM takes appropriate action according to the requirements and 
timelines stated the Code of Federal Regulations, and local regulations as applicable.  
11.7 Monitoring Procedures 
11.7.1 Study Monitoring 
An appropriate representative of Sponsor (Study Monitor) will maintain contact with the 
Investigator and will visit the study site for the purpose of discussing and/or retrieving data. 
An initiation visit will be made by the Study Monitor to discuss the protocol and the obligations 
of both the Sponsor and the Investigator.  The Investigator must allow the Study Monitor to 
perform periodic, interim monitoring visits.  The purposes of these visits are to: 
• verify that written Informed Consent was obtained prior to each subject’s participation in 
the study; 
• assess the progress of the study; 
• review the compliance with the study protocol; 
• determine whether all adverse events were appropriately reported; 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 40 
 
• determine whether the Investigator is maintaining the essential documents; 
• discuss any emergent problem; 
• check the Case Report Forms for legibility, accuracy and completeness; 
• validate the contents of the Case Report Forms against source documents; 
• assess the status of investigational product storage, dispensing and retrieval. 
All data required by the protocol must be reported accurately on the Case Report Form and must 
be consistent with the source documents.  Source documents are original documents, data and 
records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subject 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies, magnetic media, X-rays or other diagnostic images, subject files, laboratory 
records).  The Investigator will make available the source documents for inspection.  This 
information will be considered confidential. 
The Study Monitor will perform a close-out visit at the conclusion of the Investigator’s 
involvement in the study. 
11.7.2 Case Report Form 
Sponsor will provide a three-part Case Report Form for each subject.  An appropriate Sponsor 
representative will collect the first and second parts of the form; the Investigator should archive 
the third part at the investigational site.  Case Report Forms must be completed for all subjects 
who sign Informed Consent even if the subject fails to complete the study.   
Case Report Forms must be clearly printed on with a black ball point pen; erasable ink, pencil, or 
free-hand writing is not acceptable.  Any corrections or deletions are to be made by crossing out 
with a single line (so it is still legible), then initialing and dating by the Investigator or other 
authorized person.  The use of correction fluids to "white-out" mistakes in data entry is not 
permitted. 
If requested, copies of the Case Report Forms are to be made available to the appropriate and 
Regulatory Authorities. 
11.7.3 Inspection and Auditing 
The Investigator/Institution will make available for direct access all trial related records 
including source documentation for inspection by Regulatory Authorities, IRB/EC and for 
auditing by the Sponsor. This information will be considered confidential. 
11.8 Archiving of Records 
Essential documents (copies of the protocol, subject identification codes, CRF, source data, Informed 
Consent Form and other documents) pertaining to the study conduction must be kept for the 
maximum period of time as required by the study center. This time period must be at least two 
years after the last approval of the marketing application of the investigational product in an ICH 
region and until there is no pending or contemplated marketing application in an ICH region or at 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 41 
 
least two years have elapsed since the formal discontinuation of clinical development of the 
investigational product.  
No study document should be destroyed without prior written agreement between Sponsor and the 
Investigator. 
Originals of all documentation and copies of outgoing correspondence concerning the study will be 
stored and retained in a safe area in the Trial Master File of Sponsor for the lifetime of the product. In 
particular, the final report must be retained by Sponsor, or the subsequent owner, for five years 
beyond the lifetime of the investigational product. 
11.9 Study Results 
A final report of the study results will be written by Sponsor or its designee. The Clinical trial 
report (CTR) will be written within one year of the end of the notification of the study. It will be 
reviewed and approved by the Investigator when required by local authorities.  
11.10 Use and Publication of Study Results 
All unpublished documentation (including the Protocol, Case Report Form and Investigator’s 
Brochure) given to the Investigator is strictly confidential.  All recipients must agree not to 
disclose the information herein contained to any person without the prior written authorization of 
Sponsor.  The submission of these documents to the IRB is expressly permitted.  The 
Investigator agrees that Sponsor maintains the right to use the results of this study in their 
original form and/or in a global report for submission to governmental, competent, and 
regulatory authorities of any country. 
The results of the study may be presented during scientific symposia or published in a scientific 
journal only after review by Sponsor in accordance with the guidelines set forth in the applicable 
publication or financial agreement.  
11.11 Financing 
A financial agreement (separate from the protocol) will be made with the Investigator or 
designee.  Such agreement will be archived in the relevant file. 
11.12 Change in Investigator 
In the event that the Investigator is unable to continue the study, another suitable person at the 
site will become the designated Investigator, and documentation testifying to this will be 
submitted to Sponsor.  The new Investigator must be acceptable to both Sponsor and the IRB 
before the study can be continued. 
11.13 Definition of the End of the Study 
The end of the study is defined as the last subject’s image review conducted by the off-site 
blinded assessor. 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 42 
 
11.14 Premature Termination of the Study 
If Sponsor, the Investigator, or the IRB should discover conditions arising during the study that 
indicate the study should be prematurely terminated, an appropriate schedule for termination will 
be instituted.  If the Investigator prematurely terminates the study, an explanatory letter must be 
provided to Sponsor. 
Sponsor also reserves the right to discontinue this study for administrative reasons at any time.  
The Investigator will be reimbursed for reasonable expenses incurred, if it is necessary to 
prematurely terminate the study or an individual subject’s participation.  Sponsor will not 
reimburse the Investigator for the evaluation of subjects if the evaluations are not conducted in 
compliance with the present protocol. 
11.15 Information Material 
Before the beginning of the study the Investigator will be given the current version of reference 
safety document, Investigator’s Brochure. If the Investigator Brochure is revised during the 
study, the Investigator will receive a copy of the revised version.  The Investigator’s Brochure 
and the protocol are confidential communications of Sponsor.  Acceptance constitutes the 
agreement by the recipient that no unpublished information herein contained will be published or 
disclosed without Sponsor’s prior written approval except that this document may be disclosed to 
appropriate IRB as long as they are required to keep it confidential. 
11.16 Insurance 
Whenever applicable, the Sponsor will provide verification of insurance coverage for damages 
emerging from the study and involving test subjects treated with the investigational product.  The 
Investigator will be supplied with all data concerning the insurance company and policy number 
for a maximum sum insurable as stated in the Subject Information Sheet and Informed Consent 
Form. 
12 Confidentiality 
All information provided to the Investigator dealing with the investigational product will be 
regarded as confidential.  The members of the research team agree not to discuss such 
information in any way without prior written permission from Sponsor.  

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 43 
 
13 Protocol Acceptance 
I agree to conduct this clinical study according to the above protocol and to make no additions or 
changes without prior consent of Sponsor and in accordance with good clinical practice and local 
requirements/regulations. 
 
 
 
 
____________________________________ 
___________________  
Investigator 
Date 
 
 
____________________________________ 
Investigator (Printed Name) 
 
 
 
 
 
 
 
____________________________________ 
___________________  
For Bracco 
Date 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 44 
 
14 References
 
1  Lai WW, Geva T, Shirali GS, Frommelt PC, Humes RA. Guidelines and Standards for 
Performance of a Pediatric Echocardiogram: A Report from the Task Force of the Pediatric 
Council of the American Society of Echocardiography. J Am Soc Echocardiogr. 
2006;19:1413-30. 
2  McMahon CJ, Fraley K, Kovalchin JP. Use of Tissue Harmonic Imaging in Pediatric 
Echocardiography Cardiol Young. 2001; 11:562-4. 
3  Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM 
/SCCT/ SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the 
American College of Cardiology Foundation Appropriate Use Criteria Task Force, American 
Society of Echocardiography, American Heart Association, American Society of Nuclear 
Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for 
Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of 
Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance 
American College of Chest Physicians. J Am Coll Cardiol 2011;57(9):1126-66. 
4  Cohen JL, Cheirif J, Segar DS, Gillam LD, Gottdiener JS, Hausnerova E, et al. Improved left 
ventricular endocardial border delineation and opacification with `Optison a new 
echocardiographic contrast agent: results of a phase III multicenter trial. J Am Coll Cardiol. 
1998;32:746-52. 
5  Crouse LJ, Cheirif J, Hanly DE, Kisslo JA, Labovitz AJ, Raichlen JS, et al. Opacification and 
border delineation improvement in patients with suboptimal endocardial border definition in 
routine echocardiography: results of the phase III Albunex multicenter trial. J Am Coll 
Cardiol. 1993;22:1494-1500. 
6  Lindner JR, Dent JM, Moos SP, Jayaweera AR, Kaul S. Enhancement of left ventricular 
cavity opacification by harmonic imaging after venous injection of Albunex. Am J Cardiol 
1997;79:1657-62. 
7  Allen MR, Pellikka PA, Villarraga HR, Klarich KW, Foley DA, Mulvagh SL, et al. Harmonic 
imaging: echocardiographic enhanced contrast intensity and duration. Int J Card Imaging 
1999;15:215-20. 
8  Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy  
and safety of the novel ultrasound contrast agent perflutren (Definity) in patients with 
suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000;86:669-74. 
9  Candido A, Coucclo J, Galvao J Contrast Echocardiography in Segmental Analysis and 
intraventricular Gradient quantification in Hypertrophic cardiomyopathy Rev Port Cardiol 
2003 22:789-798. 
10  Clark UN, Dittrich HC Cardiac imaging using Optison Am J Cardiol 2000 86:14G-18G. 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 45 
 
 
11  Kornbluth M, Liang DH, Brown P. Contrast echocardiography is superior to tissue assessment 
of left ventricular function in mechanically ventilated patients. Am Heart J. 2000 140:291-6. 
12  Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, et al. Contrast 
echocardiography: current and future applications. J Am Soc Echocardiography. 
2000;13:331–42. 
13  Kornbluth M, Liang DH, Paloma A, Schnittger I. Native tissue harmonic imaging improves 
endocardial border definition and visualization of cardiac structures. J Am Soc Echocardiogr. 
1998;11:693–701. 
14  Reilly JP, Tunick PA, Timmermans RJ, Stein B, Rosenzweig BP, Kronzon I. Contrast 
echocardiography clarifies uninterpretable wall motion in intensive care unit patients. J Am 
Coll Cardiol. 2000;35:485–90. 
15  Yong Y, Wu D, Fernandes V, Kopelen HA, Shimoni S, Nagueh SF, et al. Diagnostic accuracy 
and cost-effectiveness of contrast echocardiography on evaluation of cardiac function in 
technically very difficult patients in the intensive care unit. Am J Cardiol. 2002;89:711–18. 
16  Grayburn PA. Product safety compromises patient safety (an unjustified black box warning on 
ultrasound contrast agents by the Food and Drug Administration). Am J Cardiol. 
2008;101:892–3. 
17  Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, American 
Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic 
Contrast Agents in Echocardiography. J Am Soc Echocardiogr. 2008 Nov;21(11):1179-201. 
18  Zilberman MV, Witt SA, Kimball TR. Is there a role for intravenous transpulmonary contrast 
imaging in pediatric stress echocardiography? J Am Soc Echocardiogr. 2003;16:9-14. 
19  McMahon CJ, Ayres NA, Bezold LI, Lewin MB, Alonzo M, Altman CA, et al. Safety and 
efficacy of intravenous contrast imaging in pediatric echocardiography. Pediatr Cardiol. 
2005;26:413-17. 
20  Kinoshita Y, Suzuki A, Nakajima T, Ono Y, Arakaki Y, Kamiya T. Collateral vessels 
assessed by myocardial contrast echocardiography in patients with coronary artery lesions 
after Kawasaki disease. Heart Vessels. 1996;11:203-10. 
21  Kutty S, Olson J, Danford C, Sandene E, Xie F, Fletcher S, et al. Ultrasound contrast and real 
time perfusion in conjunction with supine bicycle stress echocardiography for comprehensive 
evaluation of surgically corrected congenital heart disease. Eur Heart J Cardiovascular 
Imaging. 2012;13:500-9. 
22 Roger VL, Go AS, Lloyd-Jones DM et al. on behalf of the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and stroke statistics – 
2012 update: A report from the American Heart Association. Circulation. 2012: published 
online before print December, 15 2011, 10 1161/CIR.0b013e31823ac046. 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 46 
 
 
23  Prakash A, Powell AJ, Geva T. Multimodality non-invasive imaging for assessment of 
congenital heart disease. Circ Cardiovascular Imaging. 2010:112-5. 
24 St. John MG, Rutherford JD. Clinical Cardiovascular Imaging: a companion to Braunwald’s 
Heart disease – 1st ed. 2004 ISBN 0-7216-9068-8. Ch 4. 
25  Spencer KT, Bednarz J, Rafter PG, Korcarz C, Lang RM. Use of harmonic imaging without 
echocardiographic contrast to improve two-dimensional image quality. Am J Cardiol 1998; 
82: 794–799. 
26  Kasprzak JD, Paelinck B, Ten Cate FJ, Vletter WB, de Jong N, Poldemans D, et al. 
Comparison of native and contrast-enhanced harmonic echocardiography for visualization of 
left ventricular endocardial border. Am J Cardiol. 1999;83:211–17. 
27  Main ML, Asher CR, Rubin DN, Odabashian JA, Cardon LA, Thomas JD, Klein AL. 
Comparison of tissue harmonic imaging with contrast (sonicated albumin) echocardiography 
and Doppler myocardial imaging for enhancing endocardial border resolution. Am J Cardiol 
1999; 83: 218–222. 
28  Skolnick DG, Sawada SG, Feigenbaum H, Segar DS. Enhanced endocardial border 
visualization with noncontrast harmonic imaging during stress echocardiography. J Am Soc 
Echocardiogr. 1999; 12: 559–563. 
29  Thompson HL, Basmadijan AJ, Rinhard AJ, Razavi M, Avierinos JF, Pellikka PA, et al. 
Contrast echocardiography improves the accuracy and reproducibility of left ventricular 
remodeling measurements: a prospective randomly assigned, blinded study. J Am Coll 
Cardiol. 2001: 38:867-75. 
30  Hundley WG, Kizilbash AM, Afridi I, Franco F, Peshock RM, Grayburn PA. Effect of 
contrast enhancement on transthoracic echocardiographic assessment of left ventricular 
regional wall motion. Am J Cardiol. 1999;84:1365-8. 
31  Yu EH, Sioggett CE, Iwanochko RM, Rakowski H, Su SC. Feasibility and accuracy of left 
ventricular volumes and ejection fraction determination by fundamental, tissue harmonic and 
intravenous contrast imaging in difficult to image patients J Am Soc Echocardiogr. 
2000:13:216-24. 
32  Dias BF, Yu EH, Sioggett CE, Iwanochko RM, Rakowski H, Su SC. Contrast enhanced 
quantitation of left ventricular ejection fraction: what is the best method? J Am Soc 
Echocardiogr. 2001;14:1183-90. 
33  Bracco Final Clinical Trial Report 
. 
34  Bracco Final Clinical Trial Report 
 
 
 

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM ® in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 47 
 
 
35  Burri P, 1997. Structural aspects of Prenatal and Postnatal development and growth of the  
lung. Lung Growth and development. Ed. JA MCnoald, Marcel Dekker, Inc. New York. P 1-35 
[available on request) 
36 Morel DR, Schwieger I, Hohn L, Terrettaz J, Llull JB, Cornioley YA, Schneider  M. Human 
pharmacokinetics and safety evaluation of SonoVue, a new contrast agent  for ultrasound 
imaging. Invest Radiol. 2000 Jan;35(1):80-5 
37  Dolan MS, Riad K, El-Shafei A, Puri S, Tamirisa K, Bierig M, et al. Effect of intravenous 
contrast for left ventricular opacification and border definition on sensitivity and specificity of 
dobutamine stress echocardiography compared with coronary angiography in technically 
difficult patients. Am Heart J. 2001;142:908-15 
38  Bracco Final Clinical Trial Report 
.  

Protocol BR1-140  
Final 
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 48 
 
Appendix A: Investigational Product Labeling 
 
On the clinical supply box the following label will be applied: 
Carton Label 
For US Sites 
 
LUMASON TM 
 
 
IND 46,958 
 
Protocol No. BR1-140 
 
Contents: 
1 vial of 25 mg lyophilized powder 
1 pre-filled syringe with 5 mL NaCl 0.9% w/v 
1 mini spike 
 
Store at 25 C (77 F) excursions permitted from 15-30C (59-86F)  
 
CAUTION: New Drug - Limited by Federal Law to Investigational 
Use. 
Batch No.: 
 
 
Exp. Date: 
Bracco Diagnostics Inc., Monroe Twp,  NJ 08831 
 
Vial Label 
For US Sites 
 
LUMASON TM   25mg 
Protocol BR1-140 
Store at 25 C (77 F) excursions permitted from 15-30C 
(59-86F)  
For i.v. use after reconstitution with 5 mL of saline. 
CAUTION: New Drug - Limited by Federal Law to 
Investigational Use. 
 
Subject No.____  
               Initials:____ 
 
Batch No.: 
 
 
Exp. Date: 
Bracco Diagnostics Inc., Monroe Twp,  NJ 08831 
LUMASON TM 
25mg 
Protocol BR1-140 
Store at 25 C (77 F) excursions permitted from 15-30C 
(59-86F). 
For i.v. use after reconstitution with 5 mL of saline. 
CAUTION: New Drug - Limited by Federal Law to 
Investigational Use. 
 
Subject No.____  
        Initials:____  
 
Batch No.: 
 
 
Exp. Date: 
Bracco Diagnostics Inc., Monroe Twp,  NJ 08831 
 
Once a vial is assigned to a subject and is reconstituted one label will remain on the vial while the 
second one will be removed and adhered to the CRF for that subject. 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 49 
 
Appendix B: Investigational Product Preparation 
 
 
LUMASON Reconstitution 
LUMASON is supplied within a kit containing the following:  
• 
a clear glass vial labeled as LUMASON (sulfur hexafluoride lipid-type A microspheres) for 
Injectable Suspension, 
• 
a prefilled syringe labeled as Sodium Chloride Injection, USP, 0.9% Sodium Chloride and  
• 
a Mini-Spike.   
 
 
 
 
 
Glass vial 
Prefilled syringe and its 
plunger rod 
Mini-Spike  
Reconstitution steps: 
• 
Prior to LUMASON reconstitution, inspect the kit and its components for signs of damage.  Do 
not use the kit if the protective caps on the vial and prefilled syringe are not intact or if the kit 
shows other signs of damage.   
• 
Perform all LUMASON reconstitution steps under aseptic conditions.  The LUMASON vial and 
the prefilled syringe do not contain a bacteriostatic preservative.   
• 
LUMASON is reconstituted by injecting the prefilled syringe contents (5 mL saline) into the 
LUMASON vial using the following illustrated steps below.   
 
1. Connect the plunger rod to the prefilled 
syringe barrel by screwing it clockwise into 
the syringe (see Figure 1). 
 
Figure 1. 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 50 
 
2. Open the Mini-Spike transfer system 
blister and remove the syringe tip cap (see 
Figure 2). 
 
Figure 2. 
3. Open the Mini-Spike green cap and 
connect the syringe to the Mini-Spike by 
screwing it in clockwise (see Figure 3). 
 
Figure 3. 
4. Remove the flip cap plastic protective cap 
from the vial, remove the Mini-Spike spike 
protection and position the spike in the 
center of the rubber stopper of the vial. Press 
firmly inward until the spike is fully inserted 
in the stopper (see Figure 4). 
 
Figure 4. 
5. Empty the content of the syringe into the 
vial by pushing on the plunger rod (see 
Figure 5).  
 
Figure 5. 
6. Shake vigorously for 20 seconds, mixing 
all the contents in the vial (see Figure 6). A 
homogeneous white milky liquid indicates 
formation of sulfur hexafluoride lipid 
microspheres.  
 
Figure 6. 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 51 
 
7. Invert the system and slowly withdraw the 
needed volume of suspension into the 
syringe (see Figure 7). 
 
Figure 7. 
8. Unscrew the syringe from the Mini-Spike 
(see Figure 8). Immediately connect the 
syringe to the dose administration line (20 
G) and administer as directed under section 
6.4.  
 
Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 52 
 
Appendix C: Serious Adverse Event Report 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 53 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 54 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 55 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 56 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 57 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 58 
 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
INVESTIGATOR STATEMENT  
Page 1 of 2 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 59 
 
Appendix D: Investigator Statement 
 
Investigational 
Product 
LUMASONTM  
Protocol No. 
BR1-140  
Protocol  
Title: 
A Multicenter Clinical Evaluation of Safety and Efficacy of 
LumasonTM as a Contrast Agent in Pediatric Echocardiography 
Investigator: 
 
Study Site: 
 
 
COMMITMENTS 
 
By signing this document, I agree to conduct the study as outlined in the protocol and in 
accordance with: Title 21 CFR 56 - Institutional Review Boards and related guidance ( if 
applicable), and the Declaration of Helsinki, as well as, all applicable government regulations, 
Good Clinical Practice and also 
I declare: 
1) I am well qualified by scientific training and experience to conduct investigational studies in 
the clinical area of the proposed study and I am affiliated with a recognized medical school 
or with an independent institution recognized for its excellence. 
2) I have received and understand the information about pharmacology, toxicology and possible 
risks and side effects of the investigational product (e.g., as described in the Reference Safety 
Information). 
3) I shall provide information to all staff members involved in the study about their obligations 
as described in this document. 
4) I shall submit the protocol, Informed Consent Form/Subject Information Sheet and other 
required documentation to the IRB/EC for review and approval. 
5) I shall make no changes to the protocol without formal amendment (prepared in agreement 
with the Sponsor), except when necessary to protect the safety, the rights or welfare of 
subjects. In this last case I will inform the Sponsor of the change. 
6) I shall require Informed Consent from each subject prior to enrollment into the study.  The 
Informed Consent shall be documented by use of a written consent form approved by the 
IRB/EC. 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
INVESTIGATOR STATEMENT  
Page 2 of 2 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 60 
 
7) I shall use the investigational product only in compliance with the study protocol and I shall 
be responsible for the security and accountability of clinical study supplies. 
8) I shall notify the Sponsor immediately or no later than 24 hours by telephone and/or by fax of 
serious adverse events and submit written reports of serious adverse events, as outlined in the 
protocol, to Sponsor.  
9) I shall submit a written report of adverse events to the IRB, as required by applicable 
regulatory requirements. 
10) I shall complete the Sponsor’s Case Report Form (CRF) in a timely and legible manner. 
11) I shall maintain accurate source records (hospital or other institutional records), which will 
support the data entered into Case Report Forms and I shall maintain these as specified in the 
protocol. 
12) I shall retain essential documents (Investigator’s files) including study codes for at least 5 
years (or longer if required by law or agreements with the Sponsor) after completion or 
discontinuation of the trial and, in any case, no documentation will be destroyed without 
prior written agreement with the Sponsor. 
13) I shall allow monitoring visits by Sponsor’s representatives a predetermined frequency. 
14) I shall allow the authorized Sponsor representative and any competent and regulatory 
authorities to inspect the facilities and pertinent records at reasonable times and in a manner 
which ensure subject confidentiality. 
15) I shall maintain confidentiality about all information concerning the investigational product, 
such as patent applications, formulas, manufacturing process, basic scientific data and 
formulation information supplied by the Sponsor and not previously published and I shall not 
disclose this information to a third party without the written consent of the Sponsor. 
16) I shall permit the information developed in the clinical study to be used by the Sponsor in 
connection with the development of the investigational product and may be disclosed to the 
IRB and regulatory authorities. 
Following completion of the study, the data may be considered for reporting at a scientific 
meeting and/or for publication in a scientific journal.  A copy of the manuscript or abstract will 
be provided to the Sponsor for review before submission to a scientific journal for publication 
and/or a scientific meeting selection committee for oral or poster presentation.  Subgroup or 
individual Investigator publications must not interfere or compromise publication of the multi-
center results of this clinical study. 
____________________________________ 
___________________  
Investigator 
 
Date 
____________________________________ 
Investigator (Printed Name) 

Protocol BR1-140  
Final  
20th October 2014 
LumasonTM in Pediatric Echocardiography 
LumasonTM  
 
 
Document ID: BDI-PTR-AC2940.14-PT-B043127-2.0 
Confidential 
Page 61 
 
Appendix E: Administrative Structure  
 
North America 
Clinical Research Personnel 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CROs / Central Labs 
Study Monitoring 
Central Lab - TBD 
 
PK Lab- TBD 
TBD 
Central ECG - TBD 
 
Central Imaging Lab - TBD